Hematopoietic progenitors cell donation from healthy female donors during pregnancy, a report of 10 cases

Published:November 20, 2021DOI:https://doi.org/10.1016/j.jtct.2021.11.007


      • Pregnancy is an absolute contraindication for HPs collection from unrelated donors
      • Collecting HPs from related pregnant-donor is sometimes considered
      • This case collection study shows it is a relatively safe approach to collect pregnant donors
      • This study showed no alarming efficacy signals when using grafts from pregnant donors



      The golden rule when collecting hematopoietic progenitors (HPs) from healthy volunteers is “donor safety”. Pregnancy is an absolute contraindication for HPs collection from unrelated donors. Collection from a related pregnant-donor is sometimes considered based on the urgency of the transplant indication and the available alternatives. Limited data exist about the safety and efficacy of this practice.


      A retrospective chart review of the institution transplant database to summarize the safety and efficacy of HPs donation from pregnant donors.


      Ten cases of HPs donation from pregnant donors were identified. Six donated a bone marrow graft while four donated a peripheral blood graft. The median age of donors was 27.5 years. The median volume of the collected product was 521 ml (128–1160 ml), the median number of TNC in the graft was 252 × 108 (30.5–794 × 108), the median TNC concentration in the graft was 37 × 106 per ml (4.7–214.6 × 106 per ml). The median number of CD34 in the graft was 142 × 106 (6–763 × 106), the median CD34 concentration in the graft was 20 × 104 per ml (2–206 × 104 per ml). There were no safety issues or signals related to the procedure.


      HPs collection from pregnant donors is relatively safe. This case series provides valuable information for practicing transplant physicians in order to counsel pregnant donors when this scenario is encountered in clinical practice.



        • Niederwieser D
        • Baldomero H
        • Atsuta Y
        • et al.
        One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT).
        American Society of Hematology, Washington, DC2019
        • Bnd Neven
        • Leroy S
        • Hln Decaluwe
        • et al.
        Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency.
        Blood. 2009; 113: 4114-4124
        • Thomas ED
        • Buckner CD
        • Clift RA
        • et al.
        Marrow transplantation for acute nonlymphoblastic leukemia in first remission.
        New England Journal of Medicine. 1979; 301: 597-599
        • Chen S-H
        • Wang T-F
        • Yang K-L.
        Hematopoietic stem cell donation.
        International journal of hematology. 2013; 97: 446-455
        • Coleman MT
        • Trianfo VA
        • Rund DA.
        Nonobstetric emergencies in pregnancy: trauma and surgical conditions.
        American journal of obstetrics and gynecology. 1997; 177: 497-502
        • Upadya M
        • Saneesh P.
        Anaesthesia for non-obstetric surgery during pregnancy.
        Indian journal of anaesthesia. 2016; 60: 234
        • Biro P.
        Non-obstetric surgery during pregnancy.
        Acta Anaesthesiol Belg. 2002; 53: 295-297
        • Brewer M
        • Kueck A
        • Runowicz CD.
        Chemotherapy in pregnancy.
        Clinical obstetrics and gynecology. 2011; 54: 602-618
        • Pollheimer J
        • Knofler M.
        The role of the invasive, placental trophoblast in human pregnancy.
        Wiener Medizinische Wochenschrift. 2012; 162: 187-190
        • Calder C
        • Hays SR
        • Manes B
        • Lavin VA
        • Ho RH
        • Frangoul H.
        Successful bone marrow harvest during pregnancy. Bone marrow transplantation. 2005; 35: 631-632
        • Calhoun DA
        • Christensen RD.
        A randomized pilot trial of administration of granulocyte colony-stimulating factor to women before preterm delivery.
        American journal of obstetrics and gynecology. 1998; 179: 766-771
      1. Medlock ES, Kaplan DL, Cecchini M, Ulich TR, Del Castillo J, Andresen J. Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis. 1993.

      2. Novales JS, Salva AM, Modanlou HD, et al. Maternal administration of granulocyte colony-stimulating factor improves neonatal rat survival after a lethal group B streptococcal infection. 1993.

        • Pessach I
        • Shimoni A
        • Nagler A.
        Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?.
        Human reproduction update. 2013; 19: 259-267
        • McCracken S
        • Layton JE
        • Shorter SC
        • Starkey PM
        • Barlow DH
        • Mardon HJ.
        Expression of granulocyte-colony stimulating factor and its receptor is regulated during the development of the human placenta.
        Journal of endocrinology. 1996; 149: 249-258
        • McCracken SA
        • Grant KE
        • MacKenzie IZ
        • Redman CWG
        • Mardon HJ.
        Gestational regulation of granulocyte-colony stimulating factor receptor expression in the human placenta.
        Biology of reproduction. 1999; 60: 790-796
        • Litwin S
        • Lagadari M
        • Barrientos G
        • Roux ME
        • Margni R
        • Miranda S.
        Comparative Immunohistochemical Study of M-CSF and G-CSF in Feto-Maternal Interface in a Multiparity Mouse Model.
        American Journal of Reproductive Immunology. 2005; 54: 311-320
        • Kuhn P
        • Messer J
        • Paupe A
        • et al.
        A multicenter, randomized, placebo-controlled trial of prophylactic recombinant granulocyte-colony stimulating factor in preterm neonates with neutropenia.
        The Journal of pediatrics. 2009; 155 (e321): 324-330
        • Ahmad A
        • Laborada G
        • Bussel J
        • Nesin M.
        Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants.
        The Pediatric infectious disease journal. 2002; 21: 1061-1065
        • Reynoso EE
        • Shepherd FA
        • Messner HA
        • Farquharson HA
        • Garvey MB
        • Baker MA.
        Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents.
        Journal of Clinical Oncology. 1987; 5: 1098-1106
        • Scarpellini F
        • Sbracia M.
        Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial.
        Human Reproduction. 2009; 24: 2703-2708
        • Uzumaki H
        • Okabe T
        • Sasaki N
        • et al.
        Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells.
        Proceedings of the National Academy of Sciences. 1989; 86: 9323-9326
        • O'Neill C.
        The potential roles for embryotrophic ligands in preimplantation embryo development.
        Human Reproduction Update. 2008; 14: 275-288
        • Abe T
        • Azuma H
        • Watanabe A
        • et al.
        A patient with cyclic neutropenia complicated by severe persistent neutropenia successfully delivered a healthy baby.
        Internal medicine. 2000; 39: 663-666
        • Dale DC
        • Cottle TE
        • Fier CJ
        • et al.
        Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.
        American journal of hematology. 2003; 72: 82-93
        • Leitner G
        • Loidolt H
        • Greinix HT
        • Hocker P
        • Dettke M.
        Granulocyte colony-stimulating factor-induced allogeneic peripheral stem cell donation during early pregnancy.
        British journal of haematology. 2001; 115 (233-233)
        • Cavallaro AM
        • Lilleby K
        • Majolino I
        • et al.
        Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.
        Bone marrow transplantation. 2000; 25: 85-89
        • Anderlini P
        • Chan FA
        • Champlin RE
        • Korbling M
        • Strom SS.
        Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development.
        Bone marrow transplantation. 2002; 30: 661-663
        • Achtari C
        • Hohlfeld P.
        Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.
        American journal of obstetrics and gynecology. 2000; 183: 511-512
        • Nagler A
        • Korenstein-Ilan A
        • Amiel A
        • Avivi L.
        Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells.
        Experimental hematology. 2004; 32: 122-130
        • Kaplinsky C
        • Trakhtenbrot L
        • Hardan I
        • et al.
        Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF.
        Bone marrow transplantation. 2003; 32: 31-34
        • Shapira MY
        • Kaspler P
        • Samuel S
        • Shoshan S
        • Or R.
        Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors.
        American journal of hematology. 2003; 73: 33-36
        • Halter J
        • Kodera Y
        • Ispizua AU
        • et al.
        Severe events in donors after allogeneic hematopoietic stem cell donation.
        haematologica. 2009; 94: 94-101
        • Bennett CL
        • Evens AM
        • Andritsos LA
        • et al.
        Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
        British journal of haematology. 2006; 135: 642-650
        • Pulsipher MA
        • Chitphakdithai P
        • Miller JP
        • et al.
        Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.
        Blood, The Journal of the American Society of Hematology. 2009; 113: 3604-3611
        • Kato Y
        • Kuwabara T
        • Itoh T
        • et al.
        A possible relationship between abortions and placental embolism in pregnant rabbits given human granulocyte colony-stimulating factor.
        The Journal of Toxicological Sciences. 2001; 26: 39-50
        • Keller P
        • Smalling R.
        Granulocyte colony stimulating factor: animal studies for risk assessment. International review of experimental pathology. 1993; 34: 173
        • Okasaki K
        • Funato M
        • Kashima M
        • et al.
        Twenty-six-week repeat-dose toxicity study of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim) in cynomolgus monkeys.
        Toxicological Sciences. 2002; 65: 246-255